Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include f… Read more
Fortrea Holdings Inc. (FTRE) - Net Assets
Latest net assets as of September 2025: $580.80 Million USD
Based on the latest financial reports, Fortrea Holdings Inc. (FTRE) has net assets worth $580.80 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.74 Billion) and total liabilities ($2.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $580.80 Million |
| % of Total Assets | 21.18% |
| Annual Growth Rate | -25.24% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.95 |
Fortrea Holdings Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Fortrea Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fortrea Holdings Inc. (2021–2024)
The table below shows the annual net assets of Fortrea Holdings Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.36 Billion | -20.52% |
| 2023-12-31 | $1.71 Billion | -48.72% |
| 2022-12-31 | $3.34 Billion | +2.51% |
| 2021-12-31 | $3.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fortrea Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24860000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $100.00K | 0.01% |
| Other Comprehensive Income | $-282.90 Million | -20.76% |
| Other Components | $2.04 Billion | 149.90% |
| Total Equity | $1.36 Billion | 100.00% |
Fortrea Holdings Inc. Competitors by Market Cap
The table below lists competitors of Fortrea Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
$891.34 Million |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
$891.48 Million |
|
Hanwha Life
KO:088350
|
$891.63 Million |
|
Guobang Pharma Ltd
SHG:605507
|
$892.06 Million |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
$890.83 Million |
|
Coursera Inc
NYSE:COUR
|
$890.76 Million |
|
Oscotec Inc
KQ:039200
|
$890.75 Million |
|
CIE Automotive S.A
PINK:CUOTF
|
$890.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fortrea Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,714,100,000 to 1,362,400,000, a change of -351,700,000 (-20.5%).
- Net loss of 328,500,000 reduced equity.
- Other comprehensive income decreased equity by 67,400,000.
- Other factors increased equity by 44,200,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-328.50 Million | -24.11% |
| Other Comprehensive Income | $-67.40 Million | -4.95% |
| Other Changes | $44.20 Million | +3.24% |
| Total Change | $- | -20.52% |
Book Value vs Market Value Analysis
This analysis compares Fortrea Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.26x to 0.64x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $36.88 | $9.70 | x |
| 2022-12-31 | $37.81 | $9.70 | x |
| 2023-12-31 | $19.30 | $9.70 | x |
| 2024-12-31 | $15.22 | $9.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fortrea Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.18%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 2.63x
- Recent ROE (-24.11%) is below the historical average (-4.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.01% | 3.21% | 0.70x | 1.34x | $-228.06 Million |
| 2022 | 5.57% | 6.56% | 0.66x | 1.28x | $-148.06 Million |
| 2023 | -1.47% | -0.89% | 0.66x | 2.53x | $-196.61 Million |
| 2024 | -24.11% | -12.18% | 0.75x | 2.63x | $-464.74 Million |
Industry Comparison
This section compares Fortrea Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | $580.80 Million | 3.01% | 3.72x | $891.06 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |